In each case of extraintestinal manifestations of Crohn’s disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy – axial arthropathy – and primarysclerosing cholangitis, which have also been described in quiescent Crohn’s disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn’s disease have been developed in the past and only the role of infliximab has increased in Crohn’s disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, dapsone and cyclosporine or tacrolimus.

Rankin GB, et al: National Cooperative Crohn’s Disease Study: Extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914–920.
Gasché C: Extraintestinale Manifestationen der chronisch entzündlichen Darmerkrankungen. Chir Gastroenterol 1998;14:120–125.
Parsi MA, et al: Extraintestinal manifestations of Crohn’s disease respond to infliximab. Am J Gastroenterol 2002;97:S265.
Adler G, et al: Extraintestinal manifestations (in German). Z Gastroenterol 2003;41:54–61.
Su CG, Judge TA, Lichtenstein GR: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:307–327.
Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn’s disease and ulcerative colitis: A study of 700 patients. Medicine 1976;55:401–412.
Farmer RG, Hawk WA, Turnbull RB, Jr: Clinical patterns in Crohn’s disease: A statistical study of 615 cases. Gastroenterology 1975;68:627–635.
Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29–34.
Triantafillidis JK, et al: Clinical patterns of Crohn’s disease in Greece: A follow-up study of 155 cases. Digestion 2000;61:121–128.
Katz JP, Lichtenstein GR: Rheumatologic manifestations of gastrointestinal diseases. Gastroenterol Clin North Am 1998;27:533–562.
Bernstein CN, et al: The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 2001;96:1116–1122.
Tromm A, et al: Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001;39:137–144.
Chow RK, Ho VC: Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047–1060.
Powell FC, Su WP, Perry HO: Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 1996;34:395–412.
Raj V, Lichtenstein DR: Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:491–513.
Crohn BB, Ginzburg L, Oppenheimer GD: Regional enteritis: A pathological and clinical entity. JAMA 1932;99:1323–1329.
Hayllar J, et al: Side effects of non-steroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832–1847.
McCartney SA, et al: Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1115–1117.
Cipolla G, et al: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: Current perspectives. Pharmacol Res 2002;46:1–6.
Evans J, et al: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619–622.
Fornaciari G, et al: Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001;15:399–403.
Ferraz MB, et al: Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482–1486.
Clegg DO, et al: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis – A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004–2012.
Dougados M, et al: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618–627.
Dougados M, et al: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61:40–50.
Thomson GT, et al: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000;27:714–718.
Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): An open trial. J Rheumatol 2000;27:723–726.
Salvarani C, et al: Musculoskeletal manifestations in inflammatory bowel disease. Eur J Intern Med 2000;11:210–214.
Peters ND, Ejstrup L: Intravenous methyl-prednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992;21:134–138.
Maugars Y, et al: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: A double-blind study. Br J Rheumatol 1996;35:767–770.
Brandt J, et al: Efficacy of treatment of sulfasalazine versus azathioprine in ankylosing spondylitis. J Rheumatol 2000;27(suppl 59): 55.
Maini R, et al: Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932–1939.
Van Bodegraven A, Pena A: Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol 2003;6:201–212.
Van den Bosch F, et al: Crohn’s disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000;356:1821–1822.
Braun J, et al: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187–1193.
Van den Bosch F, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755–765.
Brandt J, et al: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Rheumatology 2003;42:1018–1020.
Maksymowych WP, et al: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 vs. 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766–773.
Maksymowych WP, et al: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25:714–717.
Maksymowych WP, et al: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144–155.
Bernstein CN: Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:513–516.
Rozen SM, Nahabedian MY, Manson PN: Management strategies for pyoderma gangrenosum: Case studies and review of literature. Ann Plast Surg 2001;47:310–315.
Kaddoura IL, Amm C: A rationale for adjuvant surgical intervention in pyoderma gangrenosum. Ann Plast Surg 2001;46:23–28.
Sanders CJ, Hulsmans RF: Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993;51:262–264.
Futami H, et al: Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998;33:408–411.
Eisen AZ: Fitzpatrick’s Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 2000, pp 1140–1148.
Johnson R, Lazarus G: Pulse therapy: Therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982;11:76–84.
Prystowsky JH, Kahn SN, Lazarus GS: Present status of pyoderma gangrenosum – Review of 21 cases. Arch Dermatol 1989;125:57–64.
Jolles S, Niclasse S, Benson E: Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999;140:564–565.
Abu-Elmagd K, et al: Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991;23:3328–3329.
Schuppe HC, et al: Topical tacrolimus for pyoderma gangrenosum. Lancet 1998;351:832.
Matis WL, et al: Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992;128:1060–1064.
Friedman S, et al: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1–7.
Rapini RP: Cytotoxic drugs in the treatment of skin disease. Int J Dermatol 1991;30:313–322.
Arnott ID, et al: Clinical use of infliximab in Crohn’s disease: The Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639–1646.
Hong JJ, Merel NH, Hanauer SB: Treatment of pyoderma gangrenosum complicating Crohn’s disease with infliximab. Gastroenterology 2001;120:3153.
Ljung T, et al: Pyoderma gangrenosum associated with Crohn’s disease: Effect of TNF-α blockade with infliximab. Scand J Gastroenterol 2002;37:1108–11010.
Regueiro M, et al: Successful treatment of IBD-associated pyoderma gangrenosum with infliximab. Gastroenterology 2002;122:W1357.
Triantafillidis JK, et al: Favorable response to infliximab treatment in a patient with active Crohn’s disease and pyoderma gangrenosum. Scand J Gastroenterol 2002;37:863–865.
Foster EN, et al: Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy. Gastroenterology 2002;122:W1366.
Tan MH, et al: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn’s disease with anti-tumor necrosis factor-α monoclonal antibody. Arch Dermatol 2001;137:930–933.
Regueiro M, et al: Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821–1826.
Brown RE, Lay L, Graham D: Bilateral pyoderma gangrenosum of the hand: Treatment with dapsone. J Hand Surg [Br] 1993;18:119–121.
Zhu YI, Stiller MJ: Dapsone and sulfones in dermatology: Overview and update. J Am Acad Dermatol 2001;45:420–434.
Brandt L, et al: Pyoderma gangrenosum associated with regional enteritis. Improvement in defective granulocyte function and healing of skin lesions during administration of clofazimine. Acta Med Scand 1977;201:141–144.
Kaplan B, et al: Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992;31:591–593.
Kark EC, Davis BR: Clofazimine treatment of pyoderma gangrenosum. J Am Acad Dermatol 1981;5:346–348.
Lindor KD: The Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group: Ursodiol for Primary Sclerosing Cholangitis. N Engl J Med 1997;336:691–695.
Leuschner M, et al: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology 1999;117:918–925.
Van Hoogstraten HJF, et al: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Am J Gastroenterol 2000;95:2015–2022.
Knox TA, Kaplan MM: A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494–499.
Lindor KD, et al: Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996;91:511–515.
Sandborn W, et al: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993;34:242–246.
Van Thiel DH, et al: Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455–459.
Seibold F, Oneta CM, Michetti P: Traitement des pathologies intestinales inflammatoires chroniques et de leurs complications. Forum Méd Suisse 2002;48:1115–1118.
Soukiasian SH, Foster CS, Raizman MB: Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994;118:601–611.
Fries W, et al: Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol 2002;97:499–500.
Smith JR, et al: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–257.
Sfikakis PP, et al: Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001;358:295–296.
Joseph A, et al: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449–1453.
Banares A, Abasolo L, Macarron P: Treatment of refractory posterior uveitis with anti-TNF-α (infliximab). Arthritis Rheum 2001;44:S90.
El-Shabrawi Y, Hermann Graz J: Anti-TNF therapy with infliximab in the treatment of HLA-B27 associated acute anterior uveitis: A one-year follow up. Arthritis Rheum 2001:S123.
Martin TMP, Smith JRMP, Rosenbaum JTMD: Anterior uveitis: Current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337–341.
Schreiber S: Guidelines of the DGVS. Extraintestinal manifestations. German Society of Digestive and Metabolic Diseases (in German). Z Gastroenterol 2001;39:63–65.
Dvorchik I, et al: Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002;35:380–384.
Tung BY, et al: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89–95.
You do not currently have access to this content.